v3.25.3
Operating expenses - Narrative (Details) - EUR (€)
€ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Disclosure of attribution of expenses by nature to their function [line items]        
Operating expense € 82,755 € 51,514 € 178,538 € 138,325
Research and development expenses        
Disclosure of attribution of expenses by nature to their function [line items]        
Operating expense 55,416 43,286 133,362 107,936
Operating expenses, UC clinical program     92,784  
Operating expenses, CD program     11,472  
Operating expenses, development of new indications for obefazimod     6,295  
Operating expenses, transversal activities     20,367  
Increase in operating expenses, UC clinical program 8,579      
Increase in operating expenses, development of new indications for obefazimod     5,985  
Increase in operating expenses, CD program     5,385  
Increase in operating expenses, transversal activities     5,948  
Increase in employer contributions, share-based payments     14,815  
General and administrative expense        
Disclosure of attribution of expenses by nature to their function [line items]        
Operating expense € 25,500 € 7,375 41,803 € 25,306
Increase in employer contributions, share-based payments     15,075  
Increase in professional fees expense     € 1,168